Abstract
In the era of highly active antiretroviral treatment (HAART), the prognosis of AIDS-related lymphomas might be similar to that of aggressive B-cell lymphomas in human immunodeficiency (HIV)-negative patients. In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antiretroviral Therapy, Highly Active*
-
Cyclophosphamide / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Female
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
HIV Infections / drug therapy
-
HIV Infections / mortality*
-
HIV Seronegativity
-
Humans
-
Lymphoma, AIDS-Related / drug therapy
-
Lymphoma, AIDS-Related / mortality*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / mortality*
-
Male
-
Prednisone / administration & dosage
-
Prognosis
-
Vincristine / administration & dosage
Substances
-
Granulocyte Colony-Stimulating Factor
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone